Rarecell's CTC/CTM Technology Chosen for Study into Prostate Cancer | GenomeWeb

NEW YORK (GenomeWeb News) – French biotechnology firm Rarecells today announced that Ipsen and Institut Gustave Roussy, has selected its ISET technology for a study into patients with prostate cancer.

The technology is for circulating tumor cell and circulating tumor microemboli isolation.

The goal of the study is to use ISET, which stands for Isolation by Size of Epithelial/Throphoblastic Tumor cells, for the molecular analysis and genetic characterization of circulating cancer cells, Rarecells said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.

Arizona is planning to sue Theranos for "deceptive acts" and misrepresentations of its "capabilities and operation."

If confirmed as Department of Health and Human Services Secretary, Tom Price says he will divest himself of certain holdings, according to Stat News.

Oliver Smithies, who won the Nobel Prize in 2007, has died, the New York Times reports.